MALT-1 Modulators Patent Application, 13 Inventors, April 2026
Summary
The USPTO published patent application US20260109698A1 for MALT-1 modulators, covering compounds and compositions for treating diseases affected by MALT-1 modulation. The application names 13 inventors and was filed on December 18, 2025. This is a publication of a patent application — it does not yet constitute a granted patent or create enforceable intellectual property rights.
“Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of MALT-1.”
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
The USPTO published patent application US20260109698A1 covering MALT-1 modulators — compounds, compositions, and methods for treating diseases, syndromes, conditions, and disorders affected by MALT-1 modulation. The application names 13 inventors and lists multiple CPC classifications related to heterocyclic compounds and pharmaceutical compositions.
For pharmaceutical companies developing therapeutics targeting MALT-1 pathways, this published application signals potential prior art for Freedom-to-Operate analyses. The extensive CPC classification coverage (C07D 471/14, A61K 31/4375, C07D 487/04, and others) indicates the scope of claims being pursued and may overlap with competing drug development programs in the lymphoma and autoimmune disease space. Patent applicants and their competitors should monitor the prosecution history of this application.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MALT-1 MODULATORS
Application US20260109698A1 Kind: A1 Apr 23, 2026
Inventors
Peter Christopher Ray, David Evans, Anthony Richard Bradley, Chris Radoux, Simon Richards, Catarina Santos, Jérémy Besnard, Andrew John Cooke, Sylvie Félicité Gomez, Lorène Nathalie Sabine Cazaux-Lerou, Marta Pinto, Sabrina Pucci, Claire Christiane Ginette Blanger
Abstract
Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of MALT-1. Such compounds are represented by Formula (I) and Formula (II), wherein the variables are defined herein.
CPC Classifications
C07D 471/14 A61K 31/4375 A61K 31/5025 A61K 31/519 A61K 31/5377 A61K 31/541 C07D 471/04 C07D 471/22 C07D 487/04 C07D 519/00
Filing Date
2025-12-18
Application No.
19424423
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.